MSD Collaborates with Novocure to Evaluate Tumor Treating Fields Together with Keytruda (pembrolizumab) in Non-Small Cell Lung Cancer
Shots:
- The companies plan to conduct a P-II pilot study of tumor treating fields concomitant with Keytryda for 1L treatment of intrathoracic advanced/ metastatic PD-L1+ NSCLC. The study will enroll ~66 patients with its anticipated initiation in H2’20
- The 1EPs od the study will be ORR while the 2EPs include OS- PFS- PFS@6mos.- one-year survival rate- DoR- disease control rate @18wks. and safety
- Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division- inhibiting tumor growth and causing cancer cells to die and causes minimal damage to healthy cell
Ref: PRNewswire | Image: MedPage Today
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com